- Conditions
- Vasomotor Symptoms (VMS)
- Interventions
- MT-8554
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–113
of 113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vaginal Atrophy
- Interventions
- Bazedoxifene/Conjugated Estrogen
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
- Conditions
- Vasomotor Symptoms
- Interventions
- Yoga
- Behavioral
- Lead sponsor
- Wake Forest University
- Other
- Eligibility
- 45 Years to 58 Years · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Interventions
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended Release tablets, Gabapentin
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 8
- States / cities
- Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
- Conditions
- Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
- Interventions
- Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
- Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
- Conditions
- Breast Cancer, Hot Flashes, Hot Flushes
- Interventions
- soy protein, isoflavones, Tamoxifen, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 14
- States / cities
- Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
- Conditions
- Vasomotor Symptoms Associated With Menopause, Hot Flashes
- Interventions
- Elinzanetant (BAY3427080), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 43 more
- Conditions
- Hot Flashes
- Interventions
- Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
- Conditions
- Hot Flashes
- Interventions
- Brisdelle (paroxetine mesylate), Placebo capsules
- Drug
- Lead sponsor
- Noven Therapeutics
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 32
- States / cities
- Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more
- Conditions
- Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
- Interventions
- vortioxetine
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 62 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vasomotor Symptoms, Menopause
- Interventions
- FP-101
- Drug
- Lead sponsor
- Fervent Pharmaceuticals
- Industry
- Eligibility
- 46 Years and older · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Lomita, California • Long Beach, California • West Covina, California + 8 more
- Conditions
- Vasomotor Symptoms, Endometrial Safety
- Interventions
- Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Postmenopausal Symptoms
- Interventions
- Brisdelle (paroxetine mesylate)
- Drug
- Lead sponsor
- Noven Therapeutics
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hot Flashes
- Interventions
- Cenestin 0.3 mg Tablets, Placebo
- Drug · Other
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 30 Years to 80 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 49
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Phoenix, Arizona + 40 more
- Conditions
- Hot Flashes, Stress
- Interventions
- Mindfulness-based stress reduction
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 40 Years to 69 Years · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Menopause, Hot Flashes, Vasomotor Disturbance
- Interventions
- Gabapentin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts